Published in J Clin Oncol on July 01, 2008
Efficacy of Letrozole in Recurrent Ovarian Cancer (MITO32) | NCT04421547
Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst (2014) 1.24
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer (2011) 1.09
MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int (2012) 1.07
Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res (2011) 0.97
Overview of a chemoresponse assay in ovarian cancer. Clin Transl Oncol (2014) 0.96
Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag (2009) 0.90
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer (2009) 0.88
Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Res Int (2014) 0.87
Contemporary quality of life issues affecting gynecologic cancer survivors. Hematol Oncol Clin North Am (2011) 0.84
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. J Cancer Res Clin Oncol (2012) 0.83
Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res (2016) 0.82
Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. Int J Clin Oncol (2010) 0.80
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther (2013) 0.78
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Cancer Chemother Pharmacol (2015) 0.78
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. J Exp Clin Cancer Res (2013) 0.78
Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat Chem Biol (2015) 0.76
Management of relapsed ovarian cancer: a review. Springerplus (2016) 0.75
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer (2017) 0.75
A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). J Cancer Res Clin Oncol (2016) 0.75
Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer. Invest New Drugs (2012) 0.75
Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell Lines. J Cancer (2016) 0.75
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial. Gynecol Oncol Res Pract (2017) 0.75
A phase I study of topotecan and gemcitabine in advanced solid tumors. Invest New Drugs (2010) 0.75
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol (2008) 3.64
Navigated total knee replacement. A meta-analysis. J Bone Joint Surg Am (2007) 3.39
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood (2009) 3.21
The treatment of displaced intra-articular distal radius fractures in elderly patients. Dtsch Arztebl Int (2014) 2.98
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 2.74
Primary total hip arthroplasty versus hemiarthroplasty for displaced intracapsular hip fractures in older patients: systematic review. BMJ (2010) 2.59
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res (2007) 1.57
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56
Long-term effects of neovaginal reconstruction with sigmoid loop technique on sexual function and self image in patients with gynecologic malignancies: results of a prospective study. Gynecol Oncol (2008) 1.48
Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF. Cancer Biol Ther (2006) 1.44
The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res (2003) 1.42
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res (2007) 1.40
Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med (2005) 1.40
Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res (2004) 1.39
Rebalancing the major trauma computed tomography pan-scan between panacea and Pandora's Box. Emerg Med Australas (2012) 1.38
Surgeons' beliefs and perceptions about removal of orthopaedic implants. BMC Musculoskelet Disord (2008) 1.34
Blunt liver injuries in polytrauma: results from a cohort study with the regular use of whole-body helical computed tomography. World J Surg (2003) 1.32
Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol (2009) 1.26
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res (2006) 1.24
Functional outcomes after nonoperative management of fractures of the proximal humerus. J Shoulder Elbow Surg (2009) 1.23
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res (2005) 1.22
Tibial plateau fractures: functional outcome and incidence of osteoarthritis in 125 cases. Int Orthop (2009) 1.22
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol (2010) 1.20
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer (2002) 1.18
Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med (Berl) (2005) 1.18
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
Blunt cerebrovascular injury in patients with blunt multiple trauma: diagnostic accuracy of duplex Doppler US and early CT angiography. Radiology (2005) 1.18
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res (2010) 1.18
Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies. J Surg Oncol (2010) 1.17
Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol (2007) 1.14
Personality traits and psychosocial stress: quality of life over 2 years following breast cancer diagnosis and psychological impact factors. Psychooncology (2010) 1.12
Survival trends and predictors of mortality in severe pelvic trauma: estimates from the German Pelvic Trauma Registry Initiative. Injury (2011) 1.09
Outcomes and risks of operative treatment of rupture of the anterior cruciate ligament in children and adolescents. Arthroscopy (2010) 1.08
Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol (2010) 1.06
Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer (2007) 1.06
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06
HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol (2002) 1.05
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol (2004) 1.03
Fatigue in ovarian carcinoma patients: a neglected issue? Cancer (2003) 1.02
Quality of life, anxiety, and oncological factors: a follow-up study of breast cancer patients. Psychosomatics (2010) 1.00
Diffusion tensor magnetic resonance imaging of the breast: a pilot study. Eur Radiol (2010) 0.99
Ultrasound-guided, percutaneous cryotherapy of small (< or = 15 mm) breast cancers. Invest Radiol (2005) 0.99
Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metastases. J Cancer Res Clin Oncol (2003) 0.99
Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol (2007) 0.98
The adjacent vessel sign on breast MRI: new data and a subgroup analysis for 1,084 histologically verified cases. Korean J Radiol (2010) 0.98
Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer (2010) 0.98
Safety and efficacy of gravitational shunt valves in patients with idiopathic normal pressure hydrocephalus: a pragmatic, randomised, open label, multicentre trial (SVASONA). J Neurol Neurosurg Psychiatry (2013) 0.97
The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer. Breast Care (Basel) (2010) 0.97
Early excision and late excision of heterotopic ossification after traumatic brain injury are equivalent: a systematic review of the literature. J Neurotrauma (2007) 0.97
Association between a single-pass whole-body computed tomography policy and survival after blunt major trauma: a retrospective cohort study. Scand J Trauma Resusc Emerg Med (2011) 0.96
Adherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie' Breast Care (Basel) (2008) 0.95
Retrograde fixation of distal femoral fractures: results using a new nail system. J Orthop Trauma (2003) 0.95
Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia (2006) 0.93
Sensitivity and specificity of unenhanced MR mammography (DWI combined with T2-weighted TSE imaging, ueMRM) for the differentiation of mass lesions. Eur Radiol (2009) 0.93
Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res (2006) 0.93
The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. PLoS One (2013) 0.93
Functional and anatomic results of amnion vaginoplasty in young women with Mayer-Rokitansky-Küster-Hauser syndrome. Fertil Steril (2009) 0.92
Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy. J Cancer Res Clin Oncol (2010) 0.92
Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine (2008) 0.91
Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. Support Care Cancer (2007) 0.91
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res (2008) 0.91
Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients. Breast Cancer Res Treat (2006) 0.91
Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status. Eur J Obstet Gynecol Reprod Biol (2010) 0.91
Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression? Breast Cancer Res Treat (2003) 0.90
E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res (2010) 0.90
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study. BMC Cancer (2012) 0.90
Diagnostic accuracy of plain radiographs and cineradiography in diagnosing traumatic scapholunate dissociation. Skeletal Radiol (2007) 0.90
Differential diagnosis of breast lesions 5 mm or less: is there a role for magnetic resonance imaging? J Comput Assist Tomogr (2010) 0.90
Proper estimation of blood loss on scene of trauma: tool or tale? J Trauma (2010) 0.89
Magnetic resonance imaging of inflammatory breast carcinoma and acute mastitis. A comparative study. Eur Radiol (2008) 0.89
Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res (2009) 0.89
Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study. Int J Hyperthermia (2010) 0.89
Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol (2007) 0.89
AGO Austria recommendations for genetic testing of patients with ovarian cancer. Wien Klin Wochenschr (2015) 0.88
Application of MR mammography beyond local staging: is there a potential to accurately assess axillary lymph nodes? evaluation of an extended protocol in an initial prospective study. AJR Am J Roentgenol (2011) 0.88
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer (2008) 0.87
Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Res (2009) 0.87
Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol (2002) 0.87
Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. Anticancer Res (2011) 0.87
Role of forkhead box protein 3 expression in invasive breast cancer. J Clin Oncol (2007) 0.87
Effect of contrast agent on the results of in vivo ¹H MRS of breast tumors - is it clinically significant? NMR Biomed (2011) 0.87